<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02736474</url>
  </required_header>
  <id_info>
    <org_study_id>MZhao-005</org_study_id>
    <nct_id>NCT02736474</nct_id>
  </id_info>
  <brief_title>Naltrexone and Bupropion Combination on Obese,Smoking Patients With Schizophrenia</brief_title>
  <official_title>Effect of Naltrexone and Bupropion Combination on Weight Loss and Smoking Cessation in Obese, Cigarette-smoking Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to observe the efficacy of Naltrexone and Bupropion&#xD;
      combination on weight loss and smoking cessation from baseline to week 24 compare to placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, and placebo-controlled study. Subjects with evaluation&#xD;
      and confirmation that inclusion and exclusion criteria are met, will be treated with&#xD;
      naltrexone sustained release 15mg once per day and bupropion sustained release 150mg once per&#xD;
      day in the first two weeks, and naltrexone 25mg once per day and bupropion 300mg once per day&#xD;
      during the rest of the study.The purpose of this research is to observe the efficacy of&#xD;
      Naltrexone and Bupropion on weight loss and smoking cessation compared to placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Actual">July 2018</completion_date>
  <primary_completion_date type="Actual">July 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Weight at 24 Weeks</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>evaluate all participants' weight ，weight in kilograms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numbers of Participants Who Quit Smoking</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline Craving for Nicotine Assessed by Visual Analog Scales (VAS) at 24 Weeks</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>The visual analogue scale is a scale that is used to gauge smoking craving. Patients can choose a number from 0 to 10 to show their smoking craving, in which &quot;0&quot; represents &quot;no craving&quot; and &quot;10&quot; represents &quot;intense urge&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression Status Assessed by Self-rating Depression Scale（SDS）</measure>
    <time_frame>24 weeks</time_frame>
    <description>evaluate all participants' depression status by Self-rating depression scale（SDS)，which has a theoretical value range of 20-80. The SDS total score ranges, with the higher the score representing the higher level of severity of depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety Status Assessed by Self-Rating Anxiety Scale（SAS）</measure>
    <time_frame>24 weeks</time_frame>
    <description>evaluate all participants' depression status by Self-Rating Anxiety Scale，which has a theoretical value range of 20-80. The SAS total score ranges, with the higher the score representing the higher level of severity of anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Symptoms Assessed by the Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Through a simple 40 to 50 minute talk with the patient, the physician scored 30 different symptoms on a scale of 1-7 to get their PANSS score. The total score range from 30-210. The PANSS total score ranges, with the higher the score representing the higher level of severity of clinical symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist Circumference</measure>
    <time_frame>24 weeks</time_frame>
    <description>evaluate all participants' waist circumference，waist circumference in centimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Blood Glucose Levels</measure>
    <time_frame>baseline and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Insulin Levels</measure>
    <time_frame>baseline and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glycosylated Hemoglobin</measure>
    <time_frame>baseline and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Triglycerides Levels</measure>
    <time_frame>baseline and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting HDL Cholesterol Levels</measure>
    <time_frame>baseline and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting LDL Cholesterol</measure>
    <time_frame>baseline and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Leptin</measure>
    <time_frame>baseline and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ghrelin</measure>
    <time_frame>baseline and 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Obese</condition>
  <condition>Cigarette-smoking</condition>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Naltrexone and Bupropion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naltrexone 3 tablets（15mg） once per day and Bupropion 1 capsule（150mg） once per day in the first two weeks. Then Naltrexone 5 tablets（25mg） once per day and Bupropion 2 capsules（300mg） once per day during the rest of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Naltrexone and Bupropion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Naltrexone 3 tablets+Placebo Bupropion 1 capsule once per day in the first two weeks. Then Placebo Naltrexone 5 tablets+Placebo Bupropion 2 capsule once per day during the rest of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.</description>
    <arm_group_label>Naltrexone and Bupropion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Naltrexone</intervention_name>
    <description>Placebo Naltrexone created and masked by the pharmacy to be used as a control.</description>
    <arm_group_label>Placebo Naltrexone and Bupropion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupropion</intervention_name>
    <description>1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.</description>
    <arm_group_label>Naltrexone and Bupropion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Bupropion</intervention_name>
    <description>Placebo Bupropion created and masked by the pharmacy to be used as a control.</description>
    <arm_group_label>Placebo Naltrexone and Bupropion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosis of schizophrenia by the International Classification of Diseases 10th&#xD;
             Revision (ICD-10);&#xD;
&#xD;
          -  age between 18 and 65 years old;&#xD;
&#xD;
          -  on stable antipsychotic medication treatment for at least one month;&#xD;
&#xD;
          -  BMI &gt; 28 kg/m2 according to BMI criterion for obesity in the Chinese population ， or&#xD;
             BMI&gt;27 kg/m2 in the presence of dyslipidemia, or male with waist circumference over&#xD;
             90cm;&#xD;
&#xD;
          -  smoking at least 10 cigarettes daily for one year or longer;&#xD;
&#xD;
          -  desire to lose weight and quit smoking.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Binge eating or other eating disorders;&#xD;
&#xD;
          -  Current use of weight loss or antidiabetic medications;&#xD;
&#xD;
          -  Current substance use (except nicotine or caffeine);&#xD;
&#xD;
          -  Elevated hepatic transaminase levels (&gt;2.5x normal range);&#xD;
&#xD;
          -  Clinically significant Thyroid Stimulating Hormone（TSH） and/or thyroxine4（T4）&#xD;
             abnormalities;&#xD;
&#xD;
          -  History of seizure disorder;&#xD;
&#xD;
          -  History of unstable cardiac problems or other unstable medication conditions;&#xD;
&#xD;
          -  Being pregnant or nursing (for women).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiang Du, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chief Physician</affiliation>
  </overall_official>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 23, 2016</study_first_submitted>
  <study_first_submitted_qc>April 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2016</study_first_posted>
  <results_first_submitted>January 13, 2020</results_first_submitted>
  <results_first_submitted_qc>September 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 22, 2021</results_first_posted>
  <last_update_submitted>September 25, 2021</last_update_submitted>
  <last_update_submitted_qc>September 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Mental Health Center</investigator_affiliation>
    <investigator_full_name>DU, Jiang</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 30, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT02736474/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 30, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT02736474/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Naltrexone and Bupropion</title>
          <description>Naltrexone 3 tablets（15mg） once per day and Bupropion 1 capsule（150mg） once per day in the first two weeks. Then Naltrexone 5 tablets（25mg） once per day and Bupropion 2 capsules（300mg） once per day during the rest of the study.&#xD;
Naltrexone: 3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.&#xD;
Bupropion: 1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Naltrexone and Bupropion</title>
          <description>Placebo Naltrexone 3 tablets+Placebo Bupropion 1 capsule once per day in the first two weeks. Then Placebo Naltrexone 5 tablets+Placebo Bupropion 2 capsule once per day during the rest of the study.&#xD;
Placebo Naltrexone: Placebo Naltrexone created and masked by the pharmacy to be used as a control.&#xD;
Placebo Bupropion: Placebo Bupropion created and masked by the pharmacy to be used as a control.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Naltrexone and Bupropion</title>
          <description>Naltrexone 3 tablets（15mg） once per day and Bupropion 1 capsule（150mg） once per day in the first two weeks. Then Naltrexone 5 tablets（25mg） once per day and Bupropion 2 capsules（300mg） once per day during the rest of the study.&#xD;
Naltrexone: 3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.&#xD;
Bupropion: 1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Naltrexone and Bupropion</title>
          <description>Placebo Naltrexone 3 tablets+Placebo Bupropion 1 capsule once per day in the first two weeks. Then Placebo Naltrexone 5 tablets+Placebo Bupropion 2 capsule once per day during the rest of the study.&#xD;
Placebo Naltrexone: Placebo Naltrexone created and masked by the pharmacy to be used as a control.&#xD;
Placebo Bupropion: Placebo Bupropion created and masked by the pharmacy to be used as a control.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.3" spread="5.7"/>
                    <measurement group_id="B2" value="54.1" spread="8.4"/>
                    <measurement group_id="B3" value="54.2" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Han</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>illness time duration</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.8" spread="4.6"/>
                    <measurement group_id="B2" value="25.9" spread="9.1"/>
                    <measurement group_id="B3" value="27.9" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>smoking time duration</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.6" spread="7.9"/>
                    <measurement group_id="B2" value="29.8" spread="9.8"/>
                    <measurement group_id="B3" value="29.2" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>breath CO level</title>
          <units>ppm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.1" spread="23.2"/>
                    <measurement group_id="B2" value="27.7" spread="15.6"/>
                    <measurement group_id="B3" value="27.4" spread="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>number of cigarettes smoked per week</title>
          <units>cigarettes per week</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.5" spread="5.7"/>
                    <measurement group_id="B2" value="77.6" spread="21.1"/>
                    <measurement group_id="B3" value="75.1" spread="15.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>smoking craving</title>
          <description>The visual analogue scale is a scale that is used to gauge smoking craving. Patients can choose a number from 0 to 10 to show their smoking craving, in which &quot;0&quot; represents &quot;no craving&quot; and &quot;10&quot; represents &quot;intense urge&quot;.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.3" spread="1.0"/>
                    <measurement group_id="B2" value="7.0" spread="1.4"/>
                    <measurement group_id="B3" value="6.6" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>body weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.7" spread="11.8"/>
                    <measurement group_id="B2" value="80.2" spread="11.8"/>
                    <measurement group_id="B3" value="77.5" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.8" spread="2.0"/>
                    <measurement group_id="B2" value="28.5" spread="3.7"/>
                    <measurement group_id="B3" value="27.6" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>waist circumference</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94.9" spread="4.5"/>
                    <measurement group_id="B2" value="99.8" spread="6.8"/>
                    <measurement group_id="B3" value="97.4" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <units>percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.1" spread="0.6"/>
                    <measurement group_id="B2" value="6.3" spread="1.8"/>
                    <measurement group_id="B3" value="6.2" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>fasting glucose</title>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.5" spread="1.1"/>
                    <measurement group_id="B2" value="5.5" spread="2.2"/>
                    <measurement group_id="B3" value="5.5" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HDL</title>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.9" spread="0.2"/>
                    <measurement group_id="B2" value="0.8" spread="0.1"/>
                    <measurement group_id="B3" value="0.9" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>LDL</title>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.8" spread="0.8"/>
                    <measurement group_id="B2" value="2.4" spread="0.9"/>
                    <measurement group_id="B3" value="2.6" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>insulin</title>
          <units>pmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106.8" spread="65.8"/>
                    <measurement group_id="B2" value="84.5" spread="60.4"/>
                    <measurement group_id="B3" value="95.7" spread="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglyceride</title>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.3" spread="1.1"/>
                    <measurement group_id="B2" value="1.5" spread="0.6"/>
                    <measurement group_id="B3" value="1.9" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Weight at 24 Weeks</title>
        <description>evaluate all participants' weight ，weight in kilograms</description>
        <time_frame>baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone and Bupropion</title>
            <description>Naltrexone 3 tablets（15mg） once per day and Bupropion 1 capsule（150mg） once per day in the first two weeks. Then Naltrexone 5 tablets（25mg） once per day and Bupropion 2 capsules（300mg） once per day during the rest of the study.&#xD;
Naltrexone: 3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.&#xD;
Bupropion: 1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Naltrexone and Bupropion</title>
            <description>Placebo Naltrexone 3 tablets+Placebo Bupropion 1 capsule once per day in the first two weeks. Then Placebo Naltrexone 5 tablets+Placebo Bupropion 2 capsule once per day during the rest of the study.&#xD;
Placebo Naltrexone: Placebo Naltrexone created and masked by the pharmacy to be used as a control.&#xD;
Placebo Bupropion: Placebo Bupropion created and masked by the pharmacy to be used as a control.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Weight at 24 Weeks</title>
          <description>evaluate all participants' weight ，weight in kilograms</description>
          <units>kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="5.3"/>
                    <measurement group_id="O2" value="-0.9" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Numbers of Participants Who Quit Smoking</title>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone and Bupropion</title>
            <description>Naltrexone 3 tablets（15mg） once per day and Bupropion 1 capsule（150mg） once per day in the first two weeks. Then Naltrexone 5 tablets（25mg） once per day and Bupropion 2 capsules（300mg） once per day during the rest of the study.&#xD;
Naltrexone: 3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.&#xD;
Bupropion: 1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Naltrexone and Bupropion</title>
            <description>Placebo Naltrexone 3 tablets+Placebo Bupropion 1 capsule once per day in the first two weeks. Then Placebo Naltrexone 5 tablets+Placebo Bupropion 2 capsule once per day during the rest of the study.&#xD;
Placebo Naltrexone: Placebo Naltrexone created and masked by the pharmacy to be used as a control.&#xD;
Placebo Bupropion: Placebo Bupropion created and masked by the pharmacy to be used as a control.</description>
          </group>
        </group_list>
        <measure>
          <title>Numbers of Participants Who Quit Smoking</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline Craving for Nicotine Assessed by Visual Analog Scales (VAS) at 24 Weeks</title>
        <description>The visual analogue scale is a scale that is used to gauge smoking craving. Patients can choose a number from 0 to 10 to show their smoking craving, in which &quot;0&quot; represents &quot;no craving&quot; and &quot;10&quot; represents &quot;intense urge&quot;.</description>
        <time_frame>baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone and Bupropion</title>
            <description>Naltrexone 3 tablets（15mg） once per day and Bupropion 1 capsule（150mg） once per day in the first two weeks. Then Naltrexone 5 tablets（25mg） once per day and Bupropion 2 capsules（300mg） once per day during the rest of the study.&#xD;
Naltrexone: 3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.&#xD;
Bupropion: 1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Naltrexone and Bupropion</title>
            <description>Placebo Naltrexone 3 tablets+Placebo Bupropion 1 capsule once per day in the first two weeks. Then Placebo Naltrexone 5 tablets+Placebo Bupropion 2 capsule once per day during the rest of the study.&#xD;
Placebo Naltrexone: Placebo Naltrexone created and masked by the pharmacy to be used as a control.&#xD;
Placebo Bupropion: Placebo Bupropion created and masked by the pharmacy to be used as a control.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline Craving for Nicotine Assessed by Visual Analog Scales (VAS) at 24 Weeks</title>
          <description>The visual analogue scale is a scale that is used to gauge smoking craving. Patients can choose a number from 0 to 10 to show their smoking craving, in which &quot;0&quot; represents &quot;no craving&quot; and &quot;10&quot; represents &quot;intense urge&quot;.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="2.9"/>
                    <measurement group_id="O2" value="-1.9" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Depression Status Assessed by Self-rating Depression Scale（SDS）</title>
        <description>evaluate all participants' depression status by Self-rating depression scale（SDS)，which has a theoretical value range of 20-80. The SDS total score ranges, with the higher the score representing the higher level of severity of depression.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone and Bupropion</title>
            <description>Naltrexone 3 tablets（15mg） once per day and Bupropion 1 capsule（150mg） once per day in the first two weeks. Then Naltrexone 5 tablets（25mg） once per day and Bupropion 2 capsules（300mg） once per day during the rest of the study.&#xD;
Naltrexone: 3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.&#xD;
Bupropion: 1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Naltrexone and Bupropion</title>
            <description>Placebo Naltrexone 3 tablets+Placebo Bupropion 1 capsule once per day in the first two weeks. Then Placebo Naltrexone 5 tablets+Placebo Bupropion 2 capsule once per day during the rest of the study.&#xD;
Placebo Naltrexone: Placebo Naltrexone created and masked by the pharmacy to be used as a control.&#xD;
Placebo Bupropion: Placebo Bupropion created and masked by the pharmacy to be used as a control.</description>
          </group>
        </group_list>
        <measure>
          <title>Depression Status Assessed by Self-rating Depression Scale（SDS）</title>
          <description>evaluate all participants' depression status by Self-rating depression scale（SDS)，which has a theoretical value range of 20-80. The SDS total score ranges, with the higher the score representing the higher level of severity of depression.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.4" spread="8.2"/>
                    <measurement group_id="O2" value="33.6" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anxiety Status Assessed by Self-Rating Anxiety Scale（SAS）</title>
        <description>evaluate all participants' depression status by Self-Rating Anxiety Scale，which has a theoretical value range of 20-80. The SAS total score ranges, with the higher the score representing the higher level of severity of anxiety.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone and Bupropion</title>
            <description>Naltrexone 3 tablets（15mg） once per day and Bupropion 1 capsule（150mg） once per day in the first two weeks. Then Naltrexone 5 tablets（25mg） once per day and Bupropion 2 capsules（300mg） once per day during the rest of the study.&#xD;
Naltrexone: 3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.&#xD;
Bupropion: 1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Naltrexone and Bupropion</title>
            <description>Placebo Naltrexone 3 tablets+Placebo Bupropion 1 capsule once per day in the first two weeks. Then Placebo Naltrexone 5 tablets+Placebo Bupropion 2 capsule once per day during the rest of the study.&#xD;
Placebo Naltrexone: Placebo Naltrexone created and masked by the pharmacy to be used as a control.&#xD;
Placebo Bupropion: Placebo Bupropion created and masked by the pharmacy to be used as a control.</description>
          </group>
        </group_list>
        <measure>
          <title>Anxiety Status Assessed by Self-Rating Anxiety Scale（SAS）</title>
          <description>evaluate all participants' depression status by Self-Rating Anxiety Scale，which has a theoretical value range of 20-80. The SAS total score ranges, with the higher the score representing the higher level of severity of anxiety.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1" spread="6.9"/>
                    <measurement group_id="O2" value="28.8" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Symptoms Assessed by the Positive and Negative Syndrome Scale (PANSS)</title>
        <description>Through a simple 40 to 50 minute talk with the patient, the physician scored 30 different symptoms on a scale of 1-7 to get their PANSS score. The total score range from 30-210. The PANSS total score ranges, with the higher the score representing the higher level of severity of clinical symptoms.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone and Bupropion</title>
            <description>Naltrexone 3 tablets（15mg） once per day and Bupropion 1 capsule（150mg） once per day in the first two weeks. Then Naltrexone 5 tablets（25mg） once per day and Bupropion 2 capsules（300mg） once per day during the rest of the study.&#xD;
Naltrexone: 3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.&#xD;
Bupropion: 1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Naltrexone and Bupropion</title>
            <description>Placebo Naltrexone 3 tablets+Placebo Bupropion 1 capsule once per day in the first two weeks. Then Placebo Naltrexone 5 tablets+Placebo Bupropion 2 capsule once per day during the rest of the study.&#xD;
Placebo Naltrexone: Placebo Naltrexone created and masked by the pharmacy to be used as a control.&#xD;
Placebo Bupropion: Placebo Bupropion created and masked by the pharmacy to be used as a control.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Symptoms Assessed by the Positive and Negative Syndrome Scale (PANSS)</title>
          <description>Through a simple 40 to 50 minute talk with the patient, the physician scored 30 different symptoms on a scale of 1-7 to get their PANSS score. The total score range from 30-210. The PANSS total score ranges, with the higher the score representing the higher level of severity of clinical symptoms.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.5" spread="15.0"/>
                    <measurement group_id="O2" value="57.2" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Waist Circumference</title>
        <description>evaluate all participants' waist circumference，waist circumference in centimeters</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone and Bupropion</title>
            <description>Naltrexone 3 tablets（15mg） once per day and Bupropion 1 capsule（150mg） once per day in the first two weeks. Then Naltrexone 5 tablets（25mg） once per day and Bupropion 2 capsules（300mg） once per day during the rest of the study.&#xD;
Naltrexone: 3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.&#xD;
Bupropion: 1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Naltrexone and Bupropion</title>
            <description>Placebo Naltrexone 3 tablets+Placebo Bupropion 1 capsule once per day in the first two weeks. Then Placebo Naltrexone 5 tablets+Placebo Bupropion 2 capsule once per day during the rest of the study.&#xD;
Placebo Naltrexone: Placebo Naltrexone created and masked by the pharmacy to be used as a control.&#xD;
Placebo Bupropion: Placebo Bupropion created and masked by the pharmacy to be used as a control.</description>
          </group>
        </group_list>
        <measure>
          <title>Waist Circumference</title>
          <description>evaluate all participants' waist circumference，waist circumference in centimeters</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6" spread="5.7"/>
                    <measurement group_id="O2" value="101.3" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Blood Glucose Levels</title>
        <time_frame>baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone and Bupropion</title>
            <description>Naltrexone 3 tablets（15mg） once per day and Bupropion 1 capsule（150mg） once per day in the first two weeks. Then Naltrexone 5 tablets（25mg） once per day and Bupropion 2 capsules（300mg） once per day during the rest of the study.&#xD;
Naltrexone: 3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.&#xD;
Bupropion: 1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Naltrexone and Bupropion</title>
            <description>Placebo Naltrexone 3 tablets+Placebo Bupropion 1 capsule once per day in the first two weeks. Then Placebo Naltrexone 5 tablets+Placebo Bupropion 2 capsule once per day during the rest of the study.&#xD;
Placebo Naltrexone: Placebo Naltrexone created and masked by the pharmacy to be used as a control.&#xD;
Placebo Bupropion: Placebo Bupropion created and masked by the pharmacy to be used as a control.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Blood Glucose Levels</title>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.5"/>
                    <measurement group_id="O2" value="1.0" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Insulin Levels</title>
        <time_frame>baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone and Bupropion</title>
            <description>Naltrexone 3 tablets（15mg） once per day and Bupropion 1 capsule（150mg） once per day in the first two weeks. Then Naltrexone 5 tablets（25mg） once per day and Bupropion 2 capsules（300mg） once per day during the rest of the study.&#xD;
Naltrexone: 3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.&#xD;
Bupropion: 1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Naltrexone and Bupropion</title>
            <description>Placebo Naltrexone 3 tablets+Placebo Bupropion 1 capsule once per day in the first two weeks. Then Placebo Naltrexone 5 tablets+Placebo Bupropion 2 capsule once per day during the rest of the study.&#xD;
Placebo Naltrexone: Placebo Naltrexone created and masked by the pharmacy to be used as a control.&#xD;
Placebo Bupropion: Placebo Bupropion created and masked by the pharmacy to be used as a control.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Insulin Levels</title>
          <units>pmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="74.4"/>
                    <measurement group_id="O2" value="11.0" spread="35.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Glycosylated Hemoglobin</title>
        <time_frame>baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone and Bupropion</title>
            <description>Naltrexone 3 tablets（15mg） once per day and Bupropion 1 capsule（150mg） once per day in the first two weeks. Then Naltrexone 5 tablets（25mg） once per day and Bupropion 2 capsules（300mg） once per day during the rest of the study.&#xD;
Naltrexone: 3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.&#xD;
Bupropion: 1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Naltrexone and Bupropion</title>
            <description>Placebo Naltrexone 3 tablets+Placebo Bupropion 1 capsule once per day in the first two weeks. Then Placebo Naltrexone 5 tablets+Placebo Bupropion 2 capsule once per day during the rest of the study.&#xD;
Placebo Naltrexone: Placebo Naltrexone created and masked by the pharmacy to be used as a control.&#xD;
Placebo Bupropion: Placebo Bupropion created and masked by the pharmacy to be used as a control.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glycosylated Hemoglobin</title>
          <units>percentage of hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.6"/>
                    <measurement group_id="O2" value="0.4" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Triglycerides Levels</title>
        <time_frame>baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone and Bupropion</title>
            <description>Naltrexone 3 tablets（15mg） once per day and Bupropion 1 capsule（150mg） once per day in the first two weeks. Then Naltrexone 5 tablets（25mg） once per day and Bupropion 2 capsules（300mg） once per day during the rest of the study.&#xD;
Naltrexone: 3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.&#xD;
Bupropion: 1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Naltrexone and Bupropion</title>
            <description>Placebo Naltrexone 3 tablets+Placebo Bupropion 1 capsule once per day in the first two weeks. Then Placebo Naltrexone 5 tablets+Placebo Bupropion 2 capsule once per day during the rest of the study.&#xD;
Placebo Naltrexone: Placebo Naltrexone created and masked by the pharmacy to be used as a control.&#xD;
Placebo Bupropion: Placebo Bupropion created and masked by the pharmacy to be used as a control.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Triglycerides Levels</title>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="0.9"/>
                    <measurement group_id="O2" value="-0.4" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting HDL Cholesterol Levels</title>
        <time_frame>baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone and Bupropion</title>
            <description>Naltrexone 3 tablets（15mg） once per day and Bupropion 1 capsule（150mg） once per day in the first two weeks. Then Naltrexone 5 tablets（25mg） once per day and Bupropion 2 capsules（300mg） once per day during the rest of the study.&#xD;
Naltrexone: 3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.&#xD;
Bupropion: 1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Naltrexone and Bupropion</title>
            <description>Placebo Naltrexone 3 tablets+Placebo Bupropion 1 capsule once per day in the first two weeks. Then Placebo Naltrexone 5 tablets+Placebo Bupropion 2 capsule once per day during the rest of the study.&#xD;
Placebo Naltrexone: Placebo Naltrexone created and masked by the pharmacy to be used as a control.&#xD;
Placebo Bupropion: Placebo Bupropion created and masked by the pharmacy to be used as a control.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting HDL Cholesterol Levels</title>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="1.1"/>
                    <measurement group_id="O2" value="0.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting LDL Cholesterol</title>
        <time_frame>baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone and Bupropion</title>
            <description>Naltrexone 3 tablets（15mg） once per day and Bupropion 1 capsule（150mg） once per day in the first two weeks. Then Naltrexone 5 tablets（25mg） once per day and Bupropion 2 capsules（300mg） once per day during the rest of the study.&#xD;
Naltrexone: 3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.&#xD;
Bupropion: 1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Naltrexone and Bupropion</title>
            <description>Placebo Naltrexone 3 tablets+Placebo Bupropion 1 capsule once per day in the first two weeks. Then Placebo Naltrexone 5 tablets+Placebo Bupropion 2 capsule once per day during the rest of the study.&#xD;
Placebo Naltrexone: Placebo Naltrexone created and masked by the pharmacy to be used as a control.&#xD;
Placebo Bupropion: Placebo Bupropion created and masked by the pharmacy to be used as a control.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting LDL Cholesterol</title>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.7"/>
                    <measurement group_id="O2" value="-0.2" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Leptin</title>
        <time_frame>baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone and Bupropion</title>
            <description>Naltrexone 3 tablets（15mg） once per day and Bupropion 1 capsule（150mg） once per day in the first two weeks. Then Naltrexone 5 tablets（25mg） once per day and Bupropion 2 capsules（300mg） once per day during the rest of the study.&#xD;
Naltrexone: 3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.&#xD;
Bupropion: 1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Naltrexone and Bupropion</title>
            <description>Placebo Naltrexone 3 tablets+Placebo Bupropion 1 capsule once per day in the first two weeks. Then Placebo Naltrexone 5 tablets+Placebo Bupropion 2 capsule once per day during the rest of the study.&#xD;
Placebo Naltrexone: Placebo Naltrexone created and masked by the pharmacy to be used as a control.&#xD;
Placebo Bupropion: Placebo Bupropion created and masked by the pharmacy to be used as a control.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Leptin</title>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2" spread="5.9"/>
                    <measurement group_id="O2" value="10.6" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ghrelin</title>
        <time_frame>baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone and Bupropion</title>
            <description>Naltrexone 3 tablets（15mg） once per day and Bupropion 1 capsule（150mg） once per day in the first two weeks. Then Naltrexone 5 tablets（25mg） once per day and Bupropion 2 capsules（300mg） once per day during the rest of the study.&#xD;
Naltrexone: 3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.&#xD;
Bupropion: 1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Naltrexone and Bupropion</title>
            <description>Placebo Naltrexone 3 tablets+Placebo Bupropion 1 capsule once per day in the first two weeks. Then Placebo Naltrexone 5 tablets+Placebo Bupropion 2 capsule once per day during the rest of the study.&#xD;
Placebo Naltrexone: Placebo Naltrexone created and masked by the pharmacy to be used as a control.&#xD;
Placebo Bupropion: Placebo Bupropion created and masked by the pharmacy to be used as a control.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ghrelin</title>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="352.2" spread="296.6"/>
                    <measurement group_id="O2" value="254.8" spread="106.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The 24-week study time period</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Naltrexone and Bupropion</title>
          <description>Naltrexone 3 tablets（15mg） once per day and Bupropion 1 capsule（150mg） once per day in the first two weeks. Then Naltrexone 5 tablets（25mg） once per day and Bupropion 2 capsules（300mg） once per day during the rest of the study.&#xD;
Naltrexone: 3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.&#xD;
Bupropion: 1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Naltrexone and Bupropion</title>
          <description>Placebo Naltrexone 3 tablets+Placebo Bupropion 1 capsule once per day in the first two weeks. Then Placebo Naltrexone 5 tablets+Placebo Bupropion 2 capsule once per day during the rest of the study.&#xD;
Placebo Naltrexone: Placebo Naltrexone created and masked by the pharmacy to be used as a control.&#xD;
Placebo Bupropion: Placebo Bupropion created and masked by the pharmacy to be used as a control.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4.76</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>mild abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Physician Dr Du. Jiang Du</name_or_title>
      <organization>Shanghai Mental Health Center</organization>
      <phone>86-21-64387250</phone>
      <email>dujiangdou@163.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

